We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
BiondVax Pharmaceuticals has entered definitive agreements with the Max Planck Society (MPG) and the University Medical Center Göttingen (UMG) in Germany to develop and market novel Covid-19 nanosized antibodies (NanoAbs).